Drug Type Small molecule drug |
Synonyms Isuzinaxib Hydrochloride, APX 115, APX-115 + [1] |
Target |
Mechanism NOX inhibitors(NADPH oxidase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC17H18ClN3O |
InChIKeyGMFJXGGAGPCRBM-UHFFFAOYSA-N |
CAS Registry1395946-75-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Kidney Injury | Phase 2 | US | 27 Dec 2023 | |
Acute Kidney Injury | Phase 2 | KR | 27 Dec 2023 | |
COVID-19 | Phase 2 | US | 20 Oct 2021 | |
Diabetic Nephropathies | Phase 2 | - | - |
NCT04534439 (ASN2022) Manual | Phase 2 | 140 | maacdjhlwf(rtgwjzhfum) = jcerdvusji zbmqywobwd (pvcbxqhgts ) View more | Positive | 04 Nov 2022 | ||
Placebo | maacdjhlwf(rtgwjzhfum) = ezeciozvij zbmqywobwd (pvcbxqhgts ) View more | ||||||
Phase 2 | Diabetes Mellitus, Type 2 | Chronic Kidney Diseases urinary albumin to creatinine ratio (UACR) | estimated glomerular filtration rate (eGFR) | KIM-1 | - | gyabucyxld(vtjheryedm) = pgeggcnpwu xuiztpahtj (qhdzvghbmp ) View more | Positive | 04 Nov 2022 | ||
Placebo | gyabucyxld(vtjheryedm) = vsscpksyef xuiztpahtj (qhdzvghbmp ) View more |